Skip to main content
ADALTA LIMITED logo

ADALTA LIMITED — Investor Relations & Filings

Ticker · 1AD ISIN · AU0000001AD2 LEI · 254900XT3BQIT6GR6M94 ASX Professional, scientific and technical activities
Open in API
Filings indexed 722 across all filing types
Latest filing 2026-05-17 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 1AD

About ADALTA LIMITED

https://adalta.com.au/

AdAlta Limited is a clinical-stage biotechnology company focused on the discovery and development of a new class of protein therapeutics called i-bodies. The company utilizes its proprietary i-body platform to engineer highly stable, small-format proteins that mimic the binding characteristics of shark antibodies. These i-bodies are designed to target complex disease-related proteins that are often inaccessible to traditional monoclonal antibodies. AdAlta's lead therapeutic candidate, AD-214, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic conditions. The platform's versatility allows for the creation of diverse therapeutic leads across multiple disease areas, including inflammation and oncology, by leveraging the unique structural properties of the human protein scaffold-based i-body library.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - 1AD 6 pages 18.4KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 2A Application for Quotation of Securities, detailing a new share issue (placement), number of securities to be quoted, issue price, and updated issued capital following the transaction. This is not the full financial report or an earnings release, but a regulatory announcement of a capital change (new share issue) for ASX quotation. As such, it falls under the Share Issue/Capital Change category (SHA).
2026-05-17 English
Cleansing Notice 1
Share Issue/Capital Change Classification · 85% confidence The document is a formal ASX “Cleansing Notice” under section 708A of the Corporations Act, advising of the completion of a private placement of 106,312,738 new ordinary shares and lodging an Appendix 2A. This is a direct announcement of a new share issue (capital change). Therefore it falls under “Share Issue/Capital Change” (SHA), not a funding update report, regulatory filing or other category.
2026-05-17 English
Notice of EGM & Proxy Form 22 pages 369.7KB
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a Notice of Extraordinary General Meeting (EGM) with an Explanatory Memorandum and Proxy Form sent to shareholders to solicit votes on resolutions at a general meeting. It provides detailed information on the meeting agenda, resolutions, voting exclusions, and proxy instructions. This aligns with the definition of Proxy Solicitation & Information Statement (Code: PSI).
2026-05-14 English
Webinar presentation - new hope for mesothelioma patients 16 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is formatted as a slide deck with title ‘Investor Presentation | April 2026,’ includes market opportunity, clinical data, patient case studies, strategic licensing deals, forward-looking statements, and slide numbers. This matches the definition of an Investor Presentation (IP).
2026-05-10 English
Investor webinar - new hope for mesothelioma patients 2 pages 215.4KB
Regulatory Filings
2026-05-06 English
$2.5m placement 4 pages 269.5KB
Regulatory Filings
2026-05-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.